 Heat Biologics Inc NASDAQ: HTBX will acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of Anthim obiltoxaximab Injection. The acquisition is expected to close during Q1 of 2022 and is subject to customary closing conditions. 